A prospective, open-label study assessing the Istradefylline/L-DOPA combination therapy for Parkinson's disease and blood markers of glycolytic energy homeostasis
Latest Information Update: 01 Nov 2021
At a glance
- Drugs Istradefylline (Primary) ; Levodopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
Most Recent Events
- 01 Nov 2021 New trial record
- 22 Sep 2021 Primary endpoint met (seven year changes of MDSUPDRS showed less worsening in ISTLD compared with LD) according to the results presented
- 22 Sep 2021 Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders